Genmab A/S (OTCMKTS:GNMSF) Short Interest Update

Genmab A/S (OTCMKTS:GNMSF) was the recipient of a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 169,700 shares, a growth of 7.3% from the March 31st total of 158,100 shares. Based on an average trading volume of 1,000 shares, the days-to-cover ratio is presently 169.7 days.

Genmab A/S Trading Down 0.5 %

OTCMKTS GNMSF opened at $272.81 on Thursday. Genmab A/S has a one year low of $262.00 and a one year high of $426.50. The stock has a 50 day moving average price of $291.87 and a 200-day moving average price of $297.60.

Genmab A/S (OTCMKTS:GNMSF) last posted its earnings results on Wednesday, February 14th. The company reported $3.63 EPS for the quarter. The firm had revenue of $675.29 million during the quarter. Genmab A/S had a return on equity of 18.06% and a net margin of 26.50%.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.